Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
$0.01
$0.02
$0.01
$0.03
$1.49M-0.685,603 shsN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
$1.60
-0.6%
$1.41
$1.15
$23.80
$2.65M0.511.31 million shs299,774 shs
NuCana plc stock logo
NCNA
NuCana
$0.11
-24.4%
$0.35
$0.03
$10.79
$698K1.2433.59 million shs116.86 million shs
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
$2.29
-3.4%
$0.25
$0.94
$7.76
$6.82M0.721.63 million shs108,371 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
-0.41%+14.49%-41.11%-46.74%-60.29%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
0.00%+5.96%+26.98%-7.35%-62.96%
NuCana plc stock logo
NCNA
NuCana
0.00%+130.26%+115.17%-84.89%-96.21%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
-3.38%+1,172.22%+945.66%+791.40%+19.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
1.0839 of 5 stars
0.02.00.00.03.32.50.6
NuCana plc stock logo
NCNA
NuCana
3.3557 of 5 stars
3.34.00.00.02.72.51.3
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
0.00
N/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
2.00
HoldN/AN/A
NuCana plc stock logo
NCNA
NuCana
2.50
Moderate Buy$25.0021,658.05% Upside
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NTN, GLMD, APLIF, and NCNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2025
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
$630K2.36N/AN/A($0.05) per share-0.25
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/A$33.02 per shareN/A
NuCana plc stock logo
NCNA
NuCana
N/AN/AN/AN/A$8.85 per shareN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
$19.81M0.34$0.52 per share4.38$1.76 per share1.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
-$2.80M-$0.02N/AN/AN/AN/A-209.09%N/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
-$6.91M-$16.66N/AN/AN/A-28.75%-24.98%8/26/2025 (Estimated)
NuCana plc stock logo
NCNA
NuCana
-$34.37M-$7.02N/AN/AN/AN/A-314.47%-112.60%8/13/2025 (Estimated)
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
-$2.05MN/AN/AN/A-61.42%-162.54%-49.94%N/A

Latest NTN, GLMD, APLIF, and NCNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2025Q1 2025
NuCana plc stock logo
NCNA
NuCana
-$0.0129-$0.63-$0.6171-$0.63N/AN/A
5/22/2025Q1 2025
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
3/20/2025Q4 2024
NuCana plc stock logo
NCNA
NuCana
-$2.43-$0.32+$2.11-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
N/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
NuCana plc stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
N/A
0.11
0.11
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A
7.03
7.03
NuCana plc stock logo
NCNA
NuCana
N/A
1.12
1.12
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
3.30
0.95
0.95

Institutional Ownership

CompanyInstitutional Ownership
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
N/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
76.14%
NuCana plc stock logo
NCNA
NuCana
44.00%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
6.31%

Insider Ownership

CompanyInsider Ownership
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
11.84%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
19.80%
NuCana plc stock logo
NCNA
NuCana
31.20%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
24.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Appili Therapeutics Inc. stock logo
APLIF
Appili Therapeutics
8121.27 million106.91 millionNot Optionable
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
201.65 million516,000Not Optionable
NuCana plc stock logo
NCNA
NuCana
306.08 million1.82 millionNot Optionable
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
192.98 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Appili Therapeutics stock logo

Appili Therapeutics OTCMKTS:APLIF

$0.01 0.00 (0.00%)
As of 06/13/2025

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:GLMD

$1.60 -0.01 (-0.62%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.62 +0.02 (+1.25%)
As of 06/13/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

NuCana stock logo

NuCana NASDAQ:NCNA

$0.11 -0.04 (-24.41%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$0.12 +0.01 (+5.31%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NTN Buzztime stock logo

NTN Buzztime NYSEAMERICAN:NTN

$2.29 -0.08 (-3.38%)
As of 06/13/2025

NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.